Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Net Margin: 2009-2025

Historic Net Margin for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -9,199.79%.

  • Cytokinetics' Net Margin rose 2313908.00% to -9,199.79% in Q3 2025 from the same period last year, while for Sep 2025 it was -705.98%, marking a year-over-year increase of 1670790.00%. This contributed to the annual value of -3,826.33% for FY2024, which is 313929.00% up from last year.
  • Latest data reveals that Cytokinetics reported Net Margin of -9,199.79% as of Q3 2025, which was down 5,002.94% from -180.28% recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Net Margin ranged from a high of -15.38% in Q2 2022 and a low of -57,391.16% during Q2 2024.
  • For the 3-year period, Cytokinetics' Net Margin averaged around -16,903.89%, with its median value being -9,856.30% (2025).
  • In the last 5 years, Cytokinetics' Net Margin plummeted by 4,250,143bps in 2024 and then soared by 5,721,088bps in 2025.
  • Quarterly analysis of 5 years shows Cytokinetics' Net Margin stood at -47.25% in 2021, then tumbled by 680,441bps to -6,851.66% in 2022, then slumped by 119,750bps to -8,049.16% in 2023, then surged by 706,264bps to -986.52% in 2024, then spiked by 2,313,908bps to -9,199.79% in 2025.
  • Its Net Margin was -9,199.79% in Q3 2025, compared to -180.28% in Q2 2025 and -9,856.30% in Q1 2025.